Literature DB >> 17669453

HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis.

Bo Jiang1, Valeria Y Hebert, Yuchi Li, J Michael Mathis, J Steven Alexander, Tammy R Dugas.   

Abstract

Numerous reports now indicate that HIV patients administered long-term antiretroviral therapy (ART) are at a greater risk for developing cardiovascular diseases. Endothelial dysfunction is an initiating event in atherogenesis and may contribute to HIV-associated atherosclerosis. We previously reported that ART induces direct endothelial dysfunction in rodents. In vitro treatment of human umbilical vein endothelial cells (HUVEC) with ART indicated endothelial mitochondrial dysfunction and a significant increase in the production of reactive oxygen species (ROS). In this study, we determined whether ART-induced endothelial dysfunction is mediated via mitochondria-derived ROS and whether this mitochondrial injury culminates in endothelial cell apoptosis. Two major components of ART combination therapy, a nucleoside reverse transcriptase inhibitor and a protease inhibitor, were tested, using AZT and indinavir as representatives for each. Microscopy utilizing fluorescent indicators of ROS and mitochondria demonstrated the mitochondrial localization of ART-induced ROS. MnTBAP, a cell-permeable metalloporphyrin antioxidant, abolished ART-induced ROS production. As a final step in confirming the mitochondrial origin of the ART-induced ROS, HUVEC were transduced with a cytosolic- compared to a mitochondria-targeted catalase. Transduction with the mitochondria-targeted catalase was more effective than cytoplasmic catalase in inhibiting the ROS and 8-isoprostane (8-iso-PGF2alpha) produced after treatment with either AZT or indinavir. However, both mitochondrial and cytoplasmic catalase attenuated ROS and 8-iso-PGF2alpha production induced by the combination treatment, suggesting that in this case, the formation of cytoplasmic ROS may also occur, and thus, that the mechanism of toxicity in the combination treatment group may be different compared to treatment with AZT or indinavir alone. Finally, to determine whether ART-induced mitochondrial dysfunction and ROS production culminate in apoptosis, we performed the terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL), annexin V and 4',6-diamidino-2-phenylindole (DAPI) staining, and caspase-3 activity assays. However, none of these assays showed appreciable levels of ART-induced apoptosis. Our studies thus suggest that in endothelial cells, ART induces mitochondrial dysfunction with a concomitant increase in mitochondria-derived ROS. This compromised mitochondrial function may be one important factor culminating in endothelial dysfunction, without inducing an increase in apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17669453     DOI: 10.1016/j.taap.2007.06.010

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  31 in total

1.  Biomarkers of vascular dysfunction in children infected with human immunodeficiency virus-1.

Authors:  Tracie L Miller; Gabriel Somarriba; E John Orav; Armando J Mendez; Daniela Neri; Natasha Schaefer; Lourdes Forster; Ronald Goldberg; Gwendolyn B Scott; Steven E Lipshultz
Journal:  J Acquir Immune Defic Syndr       Date:  2010-10       Impact factor: 3.731

2.  Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells.

Authors:  Kalyan Reddy Manda; Atrayee Banerjee; William A Banks; Nuran Ercal
Journal:  Free Radic Biol Med       Date:  2010-12-28       Impact factor: 7.376

3.  Development of a novel self-microemulsifying drug delivery system for reducing HIV protease inhibitor-induced intestinal epithelial barrier dysfunction.

Authors:  Bokai Lei; Weibin Zha; Yun Wang; Cong Wen; Elaine J Studer; Xuan Wang; Fang Jin; Guangji Wang; Luyong Zhang; Huiping Zhou
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

4.  Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia.

Authors:  Bo Jiang; Alok R Khandelwal; Lynette K Rogers; Valeria Y Hebert; James J Kleinedler; James H Zavecz; Weibin Shi; A Wayne Orr; Tammy R Dugas
Journal:  Toxicol Sci       Date:  2010-07-09       Impact factor: 4.849

5.  Overexpression of mitochondrial antioxidant manganese superoxide dismutase (MnSOD) provides protection against AZT- or 3TC-induced endothelial dysfunction.

Authors:  Mitzi Glover; Valeria Y Hebert; Krystle Nichols; Stephen Y Xue; Taylor M Thibeaux; James A Zavecz; Tammy R Dugas
Journal:  Antiviral Res       Date:  2014-09-27       Impact factor: 5.970

6.  Unraveling mechanisms of toxicant-induced oxidative stress in cardiovascular disease.

Authors:  Tammy R Dugas
Journal:  Curr Opin Toxicol       Date:  2017-10-12

7.  Mg supplementation protects against ritonavir-mediated endothelial oxidative stress and hepatic eNOS downregulation.

Authors:  Xi Chen; I Tong Mak
Journal:  Free Radic Biol Med       Date:  2014-01-14       Impact factor: 7.376

8.  Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells.

Authors:  Xinwen Wang; Hong Chai; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

Review 9.  Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System.

Authors:  Luc Bertrand; Madhavan Nair; Michal Toborek
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

10.  Hyperglycemia exacerbates antiretroviral drug combination induced blood-brain barrier endothelial toxicity.

Authors:  Shikha Prasad; Ravi K Sajja; Mohammad A Kaisar; Luca Cucullo
Journal:  Neurotoxicology       Date:  2016-06-23       Impact factor: 4.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.